1152618-01-3

Basic information

• Product Name: 2-fluoro-6-piperidin-4-yl-phenol
• Synonyms: 2-fluoro-6-piperidin-4-yl-phenol
• CAS NO: 1152618-01-3
• Molecular Weight: 195.237
• Mol File: 1152618-01-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-fluoro-6-piperidin-4-yl-phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-fluoro-6-piperidin-4-yl-phenol(1152618-01-3)
• EPA Substance Registry System: 2-fluoro-6-piperidin-4-yl-phenol(1152618-01-3)

Safety Data

• Hazardous Substances Data: 1152618-01-3(Hazardous Substances Data)

Upstream product

• 1376335-01-1 4-(2-benzyloxy-3-fluoro-phenyl)-1,2,3,6-tetrahydro-pyridine 
• 1152617-96-3 4-(2-benzyloxy-3-fluoro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1036724-55-6 2-benzyloxy-1-bromo-3-fluoro-benzene 
• 2040-89-3 2-bromo-6-fluorophenol 
• 1152617-99-6 4-(3-fluoro-2-hydroxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1152618-03-5 7-[4-(3-fluoro-2-hydroxyphenyl)piperidin-1-yl]-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridine-8-carbonitrile 
• 1152617-99-6 4-(3-fluoro-2-hydroxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1376335-27-1 4-(3-fluoro-2-methoxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

RADIOLABELLED mGluR2 PET LIGANDS

The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.